The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March, 2029, with company chairman Norbert Winkeljohann saying: "We're starting to ...